Protecting bone marrow during chemotherapy for advanced solid tumors
Treatments studied
Part of Cancer, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a drug that may help protect your bone marrow during chemotherapy, possibly reducing side effects like low blood counts. It is for people with certain advanced or recurrent solid tumors who are about to start a specific chemo regimen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced or recurrent solid tumor (such as lung, breast, ovarian, endometrial, cervical, head and neck, or nasopharyngeal cancer) that cannot be removed by surgery.
- You have received no more than one prior chemotherapy, and you have not had the combination of paclitaxel and carboplatin before.
- You have at least one tumor that can be measured on a scan.
- Your overall health is good enough for daily activities (ECOG score 0 or 1).
- Your blood counts and kidney, liver, and heart function meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve treatment for advanced triple-negative breast cancer. It may reduce side effects and help you tolerate treatment better.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
This trial tests a drug called trilaciclib, given before chemotherapy, to see if it can protect your bone marrow and help prevent dangerous drops in blood cell counts. If you have head and neck cancer that has returned or spread and haven't had prior drug treatment, this might help you stay stronger during chemo.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy for advanced bile duct or pancreatic cancer, potentially reducing side effects like low blood counts. It aims to make chemotherapy safer and more tolerable.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.